Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Dapagliflozin vs Rosuvastatin (Crestor): Rosuvastatin (Crestor) has the stronger overall evidence (4.5 vs 4.4/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Rosuvastatin (Crestor) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Dapagliflozin and Rosuvastatin (Crestor) have evidence — compare verdict strength side-by-side.
Off-label use mirrors approved dosing (10 mg once daily) under a clinician. A prescription drug; not an approved longevity regimen.
morning
Oral tablet (dapagliflozin)
5–20 mg once daily (up to 40 mg in selected high-risk patients), titrated to LDL/ApoB targets — under a clinician. A prescription drug; not a self-directed supplement regimen.
any
Oral tablet (rosuvastatin 5–20 mg)
Months to years
Months to years
Weeks to months
Throughout use
2–4 weeks
Months to years
1–2 years
Throughout use
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
The New England journal of medicine (2019) · Rct · n=4744
DAPA-HF randomized trial in heart failure with reduced ejection fraction
Dapagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine (2020) · Rct · n=4304
DAPA-CKD randomized trial in a broad, largely non-diabetic chronic-kidney-disease population
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
The New England journal of medicine (2022) · Rct · n=6263
DELIVER randomized trial extending dapagliflozin to mildly reduced and preserved ejection fraction
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
The New England journal of medicine (2008) · Rct · n=17802
JUPITER randomized placebo-controlled primary-prevention trial (~17,800 participants with normal LDL but elevated hsCRP)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Lancet (London, England) (2010) · Meta analysis
Meta-analysis of ~170,000 participants across 26 randomized statin trials
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
JAMA (2006) · Open label · n=507
ASTEROID open-label IVUS trial (507 enrolled; 349 with evaluable serial imaging)
Rosuvastatin (Crestor) has a higher evidence score (4.5/10 vs 4.4/10) and wins in 2 of 3 categories.
For support heart health, Rosuvastatin (Crestor) has a higher relevance score (78 vs 72).
No known interactions between Dapagliflozin and Rosuvastatin (Crestor) have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.